PIK3CA mutationBackground: 伪-Selective phosphatidylinositol 3-kinase (PI3K) inhibitors improve outcome in patients with PIK3CA-mutated, hormone receptor-positive (HR+)/Her2- metastatic breast cancer (mBC). Neve
[2]Bonotto, M., Gerratana, L., Poletto, E., et al. (2014). Measures of outcome in metastatic breast cancer: insights from a real-world scenario. The oncologist, 19(6), 608–615.[3]Criscitiello C, Marra A, Curigliano G. PIK3CA Mutation Assessment in HR+/HER2− Metastatic Breas...
[16]Jhaveri K, Juric D, Varga A, et al. Preliminary correlative analysis of clinical outcomes with PIK3CA mutation (mut) status from a phase I/Ib study of GDC-0077 in patients (pts) with hormone receptor-positive/HER...
[20]Jhaveri K, Juric D, Varga A, et al. Abstract PS5-12: Preliminary correlative analysis of clinical outcomes with PIK3CA mutation (mut) status from a phase I/Ib study of GDC0077 in patients (pts) with hormone recept...
转移性乳腺癌(Metastatic Breast Cancer,MBC)三大谬论与事实: 谬论1:我已经知道我的MBC类型——我不需要知道关于我癌症以外的任何其他事情。 事实1:你的肿瘤中可能有一种叫PIK3CA的突变,可能会影响你的癌症治疗效果。和你的医生谈谈,做个基因检测,了解更多关于你肿瘤中的PIK3CA突变状态。
Researchers observed thatPIK3CAmutation was significantly associated with a lower pathologic complete response rate in patients with HER2-positivebreast cancerwho had received neoadjuvant therapy. In the metastatic setting,PIK3CAmutation also predicted a worse objective response rate, progression-free survival,...
mutationlungalternative medicineconflict of interestbreast cancer metastaticcancerchemotherapy regimendisclosureexpert testimonyBackground 伪-selective PI3K inhibitors improve PFS in patients with HR+/Her2- metastatic breast cancer (mBC) and PIK3CA mutation. Recent studies have reported that a subset of ...
[5]Fusco, N. et al. PIK3CA mutations as a molecular target for hormone receptor-positive, HER2-negative metastatic breast cancer. Front. Oncol. 11, 644737 (2021). [6]Campbell, I. G. et al. Mutation of the PIK3CA gene in ovarian and breast cancer. Cancer Res. 64, 7678–7681 (2004)...
Abstract PS5-12: Preliminary correlative analysis of clinical outcomes with PIK3CA mutation (mut) status from a phase I/Ib study of GDC-0077 in patients (pts) with hormone receptor-positive/HER2-negative metastatic breast cancer (HR+/HER2-mBC)[J]. 2021,81:PS5-12. DOI: 10.1158/1538-7445....
Jhaveri K, Juric D, Varga A, et al. Preliminary correlative analysis of clinical outcomes with PIK3CA mutation (mut) status from a phase I/Ib study of GDC-0077 in patients (pts) with hormone receptor-positive/HER2-negative metastatic breast cancer (HR+/HER2- mBC). Cancer Res. 2021;81(...